Crystalys nets $130M more to push gout drug through late-stage tests

Summary

Crystalys secured $130M in funding to advance its gout treatment through late-stage clinical testing, with support from over 20 investment firms. The drug is already approved in multiple Asian countries but remains under development for U.S. and European markets.